Home › Trials › NCT07792590
Clinical trial Recruiting at 1 site Observational Ages 18 and up Men only

Registry of Focal Therapies for Prostate Cancer

Official title: Prospective Database / Registry of Focal Therapy for Prostate Cancer

Run by The University of Hong Kong · NCT07792590 · Data updated 2026-11-12

This registry collects real-world information from patients who had focal therapies for localized prostate cancer to help understand safety and outcomes.

Quick facts

Study typeObservational
Ages18 Years and up
SexMen only
Enrollment200 (estimated)
SponsorThe University of Hong Kong
Academic / other
Locations1 site (Hong Kong, Hong Kong)
StatusRecruiting
StartedOctober 31, 2025
Main results expectedNovember 30, 2030
Study endsFebruary 28, 2031
Registry record updatedAugust 28, 2026
Trial IDNCT07792590 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adult patients with localized prostate cancer who have undergone any focal therapy at Queen Mary Hospital and can provide written informed consent.

Probably not a fit

Patients not receiving focal therapy or unable to provide consent may not benefit from the registry data.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective registry sponsored by The University of Hong Kong to document pre-operative, intra-operative, and post-operative data for patients receiving focal therapies such as cryotherapy, HIFU, focal laser therapy, and irreversible electroporation. The study records variables including demographics, imaging and biopsy results, treatment details, anesthesia, hospital stay, and post-operative outcomes. Data from multiple centers at Queen Mary Hospital are aggregated to assess safety and feasibility of focal therapies compared with traditional whole-gland approaches. The project aims to build a comprehensive database to support future analyses of short- and long-term efficacy and quality of life after focal therapy.

Why it matters

Potential benefit: If successful, the registry could help identify safety patterns and inform future guidelines for focal therapy in localized prostate cancer.

How similar studies have gone: Prior studies suggest focal therapies can be feasible; however, robust long-term safety and efficacy data are still evolving, making this registry relatively novel in its scope.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Patients who have undergone focal therapies for prostate cancer at the Department of Surgery, Queen Mary Hospital
* Includes but not limited to: cryotherapy, high-intensity focused ultrasound (HIFU), focal laser therapy (FLA), and irreversible electroporation (IRE)
* Willing and able to provide written informed consent

Exclusion Criteria:

* Patients who are incapable to provide written informed consent.

Where it's running

  • Queen Mary Hospital
    Hong Kong, Hong Kong, Hong Kong     Recruiting

Study contacts

  • Principal investigator: Shung Lai John Leung — The University of Hong Kong, Hospital Authority
  • Study coordinator: Shung Lai John Leung, MBBS, FRCSEd, FCSHK, FHKAM
  • Email: jslleung@hku.hk
  • Phone: +852 2255 4852

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Prostate Cancer 1464The University of Hong Kong 192
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.